<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1372">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521296</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1248201</org_study_id>
    <nct_id>NCT04521296</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety after administration of DWJ1248 in patients with mild to
      moderate COVID-19 compared to the placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to SARS-CoV-2 eradication</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Time to reach undetectable SARS-CoV-2 RNA level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of SARS-CoV-2 eradication</measure>
    <time_frame>Days 4, 7, 10, and 14</time_frame>
    <description>Percent of patients with undetectable SARS-CoV-2 RNA level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement of subjective symptoms</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Mild to Moderate COVID-19</condition>
  <arm_group>
    <arm_group_label>DWJ1248</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camostat mesylate 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1248</intervention_name>
    <description>Orally, 2 tablets of DWJ1248 TID, up to 14 days</description>
    <arm_group_label>DWJ1248</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally, 2 tablets of placebo TID, up to 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over the age of 19 as of the signed date in written consent

          -  Subjects with mild or moderate COVID-19 according to RT-PCR test (Total score of NEWS
             is 0-6 or if one item is 3 points)

          -  Subjects who have symptoms within 7 days or 72 hours after diagnosis

        Exclusion Criteria:

          -  Subjects who cannot orally administer the investigational products

          -  Subjects who need administration of immunosuppressants

          -  Subjects who are allergic or sensitive to investigational products or its ingredients

          -  Subjects who have a history of drug and/or alcohol abuse within 52 weeks before
             screening

          -  Subjects who have been identified with uncontrolled concomitant diseases or
             conditions, including significant mental illness and social conditions, that may
             affect compliance with clinical trial procedures according to the determination of the
             investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

